Antithrombin III supplementation on extracorporeal membrane oxygenation: Impact on heparin dose and circuit life

ASAIO Journal

Volumn 60, Issue 1, 2014, Pages 57-62

  Byrnes, Jonathan W ^a,b   Swearingen, Christopher J ^a   Prodhan, Parthak ^a   Fiser, Richard ^a   Dyamenahalli, Umesh ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

antithrombin; blood; coagulation anticoagulation; Extracorporeal membrane oxygenation; thrombosis (extracorporeal circuit)

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; CARDIOPULMONARY BYPASS; CIRCUIT FAILURES; EXTRACORPOREAL CIRCUITS; EXTRACORPOREAL MEMBRANE OXYGENATION; TREATMENT GROUP; UNFRACTIONATED HEPARINS;

BLOOD; RESPIRATORY THERAPY;

POLYSACCHARIDES;

ANTITHROMBIN III CONCENTRATE; BLOOD CLOTTING FACTOR 10A; FRESH FROZEN PLASMA; HEPARIN; RECOMBINANT ANTITHROMBIN III;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CRYOPRECIPITATE; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; HUMAN; INFANT; INFUSION RATE; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT OUTCOME; YOUNG ADULT;

ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBINS; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES;

EID: 84891888732     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0000000000000010     Document Type: Article

References (22)

1. Sievert AN, Shackelford AG, McCall MM: Trends and emerging technologies in extracorporeal life support: Results of the 2006 ECLS survey. J Extra Corpor Technol 41: 73-78, 2009.
2. Muntean W: Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 23: 979-983, 1999.
3. Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S: Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 27: 1395-1400, 2001.
4. Baird CW, Zurakowski D, Robinson B, et al: Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 83: 912-919; discussion 919, 2007.
5. Williams MR, D'Ambra AB, Beck JR, et al: A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 70: 873-877, 2000.
6. Lemmer JH Jr, Despotis GJ: Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 123: 213-217, 2002.
7. Koster A, Fischer T, Gruendel M, et al: Management of heparin resistance during cardiopulmonary bypass: The effect of fve different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 17: 171-175, 2003.
8. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support, Extracorporeal Life Support Organization, Version 1:1. April 2009:13. Available at http://www.elso.med.umich.edu/Guidelines.htm. Accessed March 20, 2012.
9. Sievert A, Uber W, Laws S, Cochran J: Improvement in long-term ECMO by detailed monitoring of anticoagulation: A case report. Perfusion 26: 59-64, 2011.
10. Muedra V, Bonanad S, Gómez M, Villalonga V, Sánchez F, Llopis JE: Relationships between antithrombin activity, anticoagulant effcacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion 26: 487-495, 2011.
11. Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C: Use of a novel anticoagulation strategy during ECMO in a pediatric population: Single-center experience. ASAIO J 52: 513-516, 2006.
12. Niebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS: Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 35: 1024-1028, 2011.
13. Harrell FE. Regression Modeling Strategies. New York, NY, Springer, 2001, 20-27, 79-83.
14. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer-Verlag, 2001.
15. Bilen O, Loftis L, Teruya J: Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol 43: 64-69, 2011.
16. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant. Blood 70: 165-172, 1987.
17. Stiller B, Lemmer J, Merkle F, et al: Consumption of blood products during mechanical circulatory support in children: Comparison between ECMO and a pulsatile ventricular assist device. Intensive Care Med 30: 1814-1820, 2004.
18. Garvin S, Fitzgerald D, Muehlschlegel JD, et al: Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 111: 856-861, 2010.
19. Nankervis CA, Preston TJ, Dysart KC, et al: Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 53: 111-114, 2007.
20. Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J: Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 134: 950-954, 2010.
21. Levine MN, Hirsh J, Gent M, et al: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154: 49-56, 1994.
22. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS: Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45: 861-868, 2011.